tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Seizures D012640 87 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Atherosclerosis D050197 85 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Leukemia D007938 74 associated lipids
Hyperlipidemias D006949 73 associated lipids
Melanoma D008545 69 associated lipids
Colitis D003092 69 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Reperfusion Injury D015427 65 associated lipids
Pain D010146 64 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Weight Loss D015431 56 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Nerve Degeneration D009410 53 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Osteosarcoma D012516 50 associated lipids
Thrombosis D013927 49 associated lipids
Fatty Liver D005234 48 associated lipids
Precancerous Conditions D011230 48 associated lipids
Psoriasis D011565 47 associated lipids
Leukemia P388 D007941 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Hyperalgesia D006930 42 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Arthritis D001168 41 associated lipids
Hypotension D007022 41 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Lung Diseases D008171 37 associated lipids
Nervous System Diseases D009422 37 associated lipids
Heart Failure D006333 36 associated lipids
Glomerulonephritis D005921 35 associated lipids
Acne Vulgaris D000152 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Fever D005334 35 associated lipids
Burns D002056 34 associated lipids
Cataract D002386 34 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Memory Disorders D008569 33 associated lipids
Uremia D014511 33 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Diarrhea D003967 32 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Stroke D020521 32 associated lipids
Cardiomegaly D006332 31 associated lipids
Liver Diseases D008107 31 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Proteinuria D011507 30 associated lipids
Catalepsy D002375 30 associated lipids
Kidney Diseases D007674 29 associated lipids
Obesity D009765 29 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Brain Diseases D001927 27 associated lipids
Endotoxemia D019446 27 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Ascites D001201 25 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Cholestasis D002779 23 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Fibrosis D005355 23 associated lipids
Cystitis D003556 23 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Hypersensitivity D006967 22 associated lipids
Erythema D004890 22 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Milićević NM and Milićević Z Stereological study of splenic tissue compartments in FK506-treated rats. 1997 Histol. Histopathol. pmid:9302561
Wingard JR et al. Lack of interaction between tacrolimus (FK506) and methotrexate in bone marrow transplant recipients. 1997 Bone Marrow Transplant. pmid:9232256
Yamagami S et al. Mechanism of concordant corneal xenograft rejection in mice: synergistic effects of anti-leukocyte function-associated antigen-1 monoclonal antibody and FK506. 1997 Transplantation pmid:9233699
Wijnen RM and Ericzon BG Update of tacrolimus in pancreas transplantation. 1997 Diabet. Med. pmid:9400914
Sawabe T et al. Sinus arrest during tacrolimus (FK506) and digitalis treatment in a bone marrow transplant recipient. 1997 Transplantation pmid:9233725
Misao T et al. Efficacy of combining donor-specific presensitization with a simultaneous single injection of tacrolimus on pulmonary allografts. 1997 J. Heart Lung Transplant. pmid:9402508
Suzuki J et al. Inhibition of accelerated coronary atherosclerosis with short-term blockade of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 in a heterotopic murine model of heart transplantation. 1997 J. Heart Lung Transplant. pmid:9402514
Cohen SB et al. Autocrine and paracrine regulation of human T cell IL-10 production. 1997 J. Immunol. pmid:9190906
Zucker K et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. 1997 Transpl. Immunol. pmid:9402690
Miyata Y et al. Phosphorylation of the immunosuppressant FK506-binding protein FKBP52 by casein kinase II: regulation of HSP90-binding activity of FKBP52. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9405642
Taylor DO The use of tacrolimus and mycophenolate mofetil after cardiac transplantation. 1997 Curr. Opin. Cardiol. pmid:9192485
Harihara Y and Makuuchi M [Partial liver transplantation]. 1997 Nippon Naika Gakkai Zasshi pmid:9340350
Hayashi S et al. Adenovirus-mediated gene transfer to the xenogeneic liver in liver xenotransplantation: the transduction of complement regulatory factor genes (DAF and HRF20). 1997 Transplant. Proc. pmid:9193595
Wallemacq PE et al. IMx tacrolimus II vs IMx tacrolimus microparticle enzyme immunoassay evaluated in renal and hepatic transplant patients. 1997 Clin. Chem. pmid:9342026
Hohage H et al. Effects of cyclosporin A and FK 506 on lipid metabolism and fibrinogen in kidney transplant recipients. 1997 Clin Transplant pmid:9193847
Gold BG et al. A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration. 1997 Exp. Neurol. pmid:9344552
Mrvos R et al. Tacrolimus (FK 506) overdose: a report of five cases. 1997 J. Toxicol. Clin. Toxicol. pmid:9204100
Stegall MD et al. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. 1997 Transplantation pmid:9422404
Sikorski R and Peters R A cell growth switch. 1997 Science pmid:9206844
Shield CF et al. Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506)-based versus cyclosporine-based immunosuppression. FK506 Kidney Transplant Study Group. 1997 Transplantation pmid:9422413
Shafiee A et al. Chemical and biological characterization of two FK506 analogs produced by targeted gene disruption in Streptomyces sp. MA6548. 1997 J. Antibiot. pmid:9207912
Stegall MD et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. 1997 Transplantation pmid:9422416
Uberti JP et al. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies. 1997 Bone Marrow Transplant. pmid:9208118
Shihab FS et al. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. 1997 Transplantation pmid:9422427
Ohashi Y et al. Successful treatment of steroid-resistant severe acute GVHD with 24-h continuous infusion of FK506. 1997 Bone Marrow Transplant. pmid:9085743
Vu MD et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. 1997 Transplantation pmid:9422432
Oz HS and Hughes WT Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. 1997 J. Infect. Dis. pmid:9086147
Wagner K et al. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. 1997 J. Heart Lung Transplant. pmid:9087870
Yasutomi M et al. Evaluation of tetrahydropyranyladriamycin as an immunosuppressant in concordant xenotransplantation. 1997 J. Heart Lung Transplant. pmid:9087871
Kitagaki K et al. Facilitation of apoptosis by cyclosporins A and H, but not FK506 in mouse bronchial eosinophils. 1997 Eur. J. Pharmacol. pmid:9430427
Midtvedt K et al. Successful pregnancies in a combined pancreas and renal allograft recipient and in a renal graft recipient on tacrolimus treatment. 1997 Nephrol. Dial. Transplant. pmid:9430893
Rudant E et al. Study of the correlation between MEIA and ELISA methods for FK 506 determination in liver transplant recipients. 1997 J Clin Pharm Ther pmid:9373812
Cetinkale O et al. Involvement of neutrophils in ischemic injury. I. Biochemical and histopathological investigation of the effect of FK506 on dorsal skin flaps in rats. 1997 Ann Plast Surg pmid:9374148
Kuromitsu S et al. 3-(13-Hydroxytridecyl)-1-[13-(3-pyridyl)tridecyl]pyridinium chloride (YM-53792), a novel inhibitor of NF-AT activation. 1997 Biochem. Pharmacol. pmid:9374420
Steffen R et al. Autoimmune enteropathy in a pediatric patient: partial response to tacrolimus therapy. 1997 Clin Pediatr (Phila) pmid:9152557
Canzanello VJ et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). 1997 Liver Transpl Surg pmid:9377752
Chow FS et al. Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. 1997 Drug Metab. Dispos. pmid:9152601
De Gasperi A and Rohrer RJ Scenario number two: sepsis and multiorgan failure after liver transplantation. 1997 Liver Transpl Surg pmid:9377761
Woo M et al. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. 1997 Bone Marrow Transplant. pmid:9466284
Araki T et al. Effects of vinconate on age-related alterations in [3H]MK-801, [3H]glycine, sodium-dependent D-[3H]aspartate, [3H]FK-506 and [3H]PN200-110 binding in rats. 1997 Mech. Ageing Dev. pmid:9152958
Lang P and Baron C Molecular mechanisms of immunosuppressive chemical agents recently introduced in clinical transplantation protocols. 1997 Nephrol. Dial. Transplant. pmid:9351062
Banholzer R et al. Rapamycin destabilizes interleukin-3 mRNA in autocrine tumor cells by a mechanism requiring an intact 3' untranslated region. 1997 Mol. Cell. Biol. pmid:9154824
Waer M New immunosuppressive agents for organ transplantation. 1997 Acta Clin Belg pmid:9351290
Delehanty LL et al. Apoptosis in a Fas-resistant, T-cell receptor-sensitive human leukaemic T-cell clone. 1997 Immunology pmid:9155645
Sheiner PA et al. Increased risk of early rejection correlates with recovery of CD3 cell count after liver transplant in patients receiving OKT3 induction. 1997 Transplantation pmid:9355846
Newell KA et al. Treatment with either anti-CD4 or anti-CD8 monoclonal antibodies blocks alphabeta T cell-mediated rejection of intestinal allografts in mice. 1997 Transplantation pmid:9381541
Iyengar AR et al. Striking augmentation of hematopoietic cell chimerism in noncytoablated allogeneic bone marrow recipients by FLT3 ligand and tacrolimus. 1997 Transplantation pmid:9158008
Karlsson H and Nässberger L FK506 suppresses the mitogen-induced increase in lymphocyte adhesiveness to endothelial cells, but does not affect endothelial cell activation in response to inflammatory stimuli. 1997 Transplantation pmid:9355847
van Hooff JP Pneumocystis carinii pneumonia after renal transplantation. 1997 Transplantation pmid:9158038
Siddiqui MA et al. Lymphomatoid papulosis and FK 506. 1997 Int. J. Dermatol. pmid:9159004
Okudaira H et al. Control of allergic diseases by regulation of cytokine gene transcription. 1997 Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M pmid:9383912
Lee JW et al. Tacrolimus (FK506): validation of a sensitive enzyme-linked immunosorbent assay kit for and application to a clinical pharmacokinetic study. 1997 Ther Drug Monit pmid:9108651
Thyagarajan GK et al. FK506-induced fulminant leukoencephalopathy after single-lung transplantation. 1997 Ann. Thorac. Surg. pmid:9386723
Tomás ML [Immunosuppressive agents: side effects]. 1997 An R Acad Nac Med (Madr) pmid:9616947
Graef IA et al. Proximity and orientation underlie signaling by the non-receptor tyrosine kinase ZAP70. 1997 EMBO J. pmid:9312021
Wong BR et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. 1997 J. Biol. Chem. pmid:9312132
Hansen LJ et al. Early pharmacokinetic profiles of enteral tacrolimus after multivisceral transplantation. 1997 Transplant. Proc. pmid:9142303
Durham HD et al. The immunosuppressant FK506 prolongs transgene expression in brain following adenovirus-mediated gene transfer. 1997 Neuroreport pmid:9243594
Tanaka K et al. Calcineurin inhibitor, FK506, prevents reduction in the binding capacity of cyclic AMP-dependent protein kinase in ischemic gerbil brain. 1997 J. Cereb. Blood Flow Metab. pmid:9143223
Yu C et al. Glucocorticoids fail to enhance the effect of FK506 and methotrexate in prevention of graft-versus-host disease after DLA-nonidentical, unrelated marrow transplantation. 1997 Bone Marrow Transplant. pmid:9244417
Galley Y et al. Jun NH2-terminal kinase is constitutively activated in T cells transformed by the intracellular parasite Theileria parva. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9144200
Floren LC et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. 1997 Clin. Pharmacol. Ther. pmid:9246018
Soman KV et al. Template-based docking of a prolactin receptor proline-rich motif octapeptide to FKBP12: implications for cytokine receptor signaling. 1997 Protein Sci. pmid:9144770
Cao S et al. Potential effect of cyclosporin A in formation of cholesterol gallstones in pediatric liver transplant recipients. 1997 Dig. Dis. Sci. pmid:9246038
Wong PW and Pessah IN Noncoplanar PCB 95 alters microsomal calcium transport by an immunophilin FKBP12-dependent mechanism. 1997 Mol. Pharmacol. pmid:9145907
McKee M et al. Steroid withdrawal in tacrolimus (FK506)-treated pediatric liver transplant recipients. 1997 J. Pediatr. Surg. pmid:9247215
Marienfeld R et al. Cyclosporin A interferes with the inducible degradation of NF-kappa B inhibitors, but not with the processing of p105/NF-kappa B1 in T cells. 1997 Eur. J. Immunol. pmid:9247567
Talbot D et al. Alopecia as a consequence of tacrolimus therapy in renal transplantation? 1997 Transplantation pmid:9415574
Mignat C Clinically significant drug interactions with new immunosuppressive agents. 1997 Drug Saf pmid:9113494
Gruessner RW and Sharp HL Living-related intestinal transplantation: first report of a standardized surgical technique. 1997 Transplantation pmid:9415566
Meiser BM et al. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation. 1997 J. Heart Lung Transplant. pmid:9286771
Morris-Stiff G et al. Conversion from cyclosporin to tacrolimus in a patient with prolonged acute tubular necrosis. 1997 Transpl. Int. pmid:9287408
Gerlach J et al. Systemic liberation of interleukin-8 in the perioperative phase of liver transplantation. 1997 Transpl. Int. pmid:9287409
Michel MC et al. Comparison of old and new IMX assays for monitoring of tacrolimus levels. 1997 Transpl. Int. pmid:9287412
Brunet M [Tacrolimus (FK506): clinical, pharmacological and analytical aspects]. 1997 Med Clin (Barc) pmid:9289523
Yagi M et al. Effect of a glutamine-enriched diet on small bowel allograft during immunosuppressive therapy. 1997 Nutrition pmid:9290090
Kramer MR et al. Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506). 1997 Transplant. Proc. pmid:9290780
Ilan Y et al. Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat. 1997 Hepatology pmid:9328318
Vella JP and Sayegh MH Maintenance pharmacological immunosuppressive strategies in renal transplantation. 1997 Postgrad Med J pmid:9338020
Atkison P et al. Small bowel transplantation in children. 1997 Pediatr Transplant pmid:10084770
Webber SA 15 years of pediatric heart transplantation at the University of Pittsburgh: lessons learned and future prospects. 1997 Pediatr Transplant pmid:10084782
Mori A et al. IL-2-induced IL-5 synthesis, but not proliferation, of human CD4+ T cells is suppressed by FK506. 1997 J. Immunol. pmid:9103428
Hess DA et al. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation. 1997 J. Pharmacol. Exp. Ther. pmid:9103542
Kawamura N et al. Extremely high serum level of IgE during immunosuppressive therapy: paradoxical effect of cyclosporine A and tacrolimus. 1997 Int. Arch. Allergy Immunol. pmid:9104801
Beals CR et al. Nuclear localization of NF-ATc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction. 1997 Genes Dev. pmid:9106655
Aiko S et al. Effects of cyclosporine or FK506 in chronic colitis. 1997 J. Pharmacol. Exp. Ther. pmid:9023326
Budde K et al. Differing proteinuria control with cyclosporin and tacrolimus. 1997 Lancet pmid:9024386
Alak AM et al. A highly sensitive enzyme-linked immunosorbent assay for the determination of tacrolimus in atopic dermatitis patients. 1997 Ther Drug Monit pmid:9029754
Padhi ID et al. Interaction between tacrolimus and erythromycin. 1997 Ther Drug Monit pmid:9029762
Tsuchida Y et al. Limb allografts in rats treated with anti-ICAM-1 and anti-LFA-1 monoclonal antibodies. 1997 J Reconstr Microsurg pmid:9044184
Wang W et al. c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. 1997 Immunity pmid:9047238
Steiner JP et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9050897
Tsamandas AC et al. Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction. 1997 J. Heart Lung Transplant. pmid:9257254
Trede NS et al. Tacrolimus (FK506) in allogeneic bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation. 1997 Bone Marrow Transplant. pmid:9257897
Freiberg RA et al. Transcriptional control in keratinocytes and fibroblasts using synthetic ligands. 1997 J. Clin. Invest. pmid:9169490
Wang JH and Kelly PT Postsynaptic calcineurin activity downregulates synaptic transmission by weakening intracellular Ca2+ signaling mechanisms in hippocampal CA1 neurons. 1997 J. Neurosci. pmid:9169521
Dodd DA Rapid resolution of gingival hyperplasia after switching from cyclosporine A to tacrolimus. 1997 J. Heart Lung Transplant. pmid:9171281
Savoldi E et al. [Dental and oral aspects in pediatric liver transplant patients. A comparison between the effects of cyclosporine A and FK 506]. 1997 Minerva Stomatol pmid:9173223
Rezeig MA et al. Kaposi's sarcoma in liver transplant recipients on FK506: two case reports. 1997 Transplantation pmid:9175820
Rühlmann A and Nordheim A Effects of the immunosuppressive drugs CsA and FK506 on intracellular signalling and gene regulation. 1997 Immunobiology pmid:9442391